Literature DB >> 9536988

[What's new about microsatellite instability significance in human carcinogenesis?].

C Vaurs1, Y J Bignon.   

Abstract

Microsatellite instabilities (MIN) represent a new type of mutation characterized by genomic instability (or replication error phenotype, RER+). First identified in sporadic and familial colorectal tumors, the RER+ phenotype has been sought in multiple types of cancers. Thus, two types of instability mechanisms have been shown: one due to inactivation of the mismatch repair system (phenotype RER+) and a second still unclear (instability of tri- and tetra-nucleotide repeats). In both cases, MIN seem to be the reflect of a new tumorigenesis pathway. In the context of mismatch repair defect, numerous observations show that, although instabilities seem to be random, they play a direct role in the tumoral process by altering genes that control cell growth and apoptosis. Today, MIN, as well as the detection of mutations in the DNA mismatch repair genes, can be used as diagnosis tools in oncology and provide usefull indications to adapt the chemotherapy to the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9536988

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Feasibility of a cost-effective approach to evaluate short tandem repeat markers suitable for chimerism follow-up.

Authors:  Ariela F Fundia; Carlos De Brasi; Irene Larripa
Journal:  Mol Diagn       Date:  2004

2.  No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.

Authors:  Bárbara Mesquita; Isabel Veiga; Deolinda Pereira; Ana Tavares; Isabel M Pinto; Carla Pinto; Manuel R Teixeira; Sérgio Castedo
Journal:  BMC Cancer       Date:  2005-08-11       Impact factor: 4.430

3.  Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.

Authors:  R A Bras-Gonçalves; C Rosty; P Laurent-Puig; P Soulié; B Dutrillaux; M F Poupon
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.